Objectives: Ganciclovir is the most widely used treatment for cytomegalovirus infections. However, neutropenia is a frequent associated adverse effect leading to a decrease in the ganciclovir dose or discontinuation of the therapy, thereby favouring viral resistance. In the present study, the objectives were: (i) to describe the pharmacokinetics of blood and intracellular ganciclovir and its metabolites; and (ii) to explore the relationship between exposure to ganciclovir and/or its metabolites and evolution of the neutrophil count under treatment.
Introduction
Cytomegalovirus (CMV) infection significantly increases the morbidity and mortality in solid organ transplant (SOT) patients. 1 The two most used drugs for CMV prophylactic or curative treatment in SOT patients are ganciclovir and its prodrug valganciclovir. Because valganciclovir has better bioavailability, it is preferred for both prophylactic and pre-emptive therapies. 2 Valganciclovir and ganciclovir pharmacodynamics are well understood. First, valganciclovir is hydrolysed into ganciclovir by intestinal and hepatic esterases. 3 In CMV-infected cells, ganciclovir is then phosphorylated into ganciclovir monophosphate. It is known as the limiting step, because this first phosphorylation is largely dependent on the viral protein kinase, pUL97. 4, 5 Ganciclovir monophosphate is phosphorylated into ganciclovir triphosphate, which is the active form that incorporates into DNA.
The main side effect of ganciclovir therapy is haematological toxicity and particularly neutropenia. It can occur in up to 50% of patients given ganciclovir, 6 leading to a decrease in the ganciclovir dose or discontinuation of the therapy, thereby favouring viral resistance. Some studies have explored the relationship between ganciclovir blood concentrations and the occurrence of neutropenia. In a study of 372 SOT patients, Wiltshire et al. 7 only noted that higher ganciclovir exposure resulted in a weak increase of neutropenia (and leukopenia). Therefore, intracellular metabolism of ganciclovir and its metabolites could be associated with neutropenia. However, very little is known about the pharmacokinetics (PK) of intracellular ganciclovir and its metabolites in patients' blood cells.
In this context, the objectives of the present study were: (i) to describe the PK of blood and intracellular ganciclovir and its metabolites in a cohort of renal transplant patients; and (ii) to explore the relationship between exposure to ganciclovir and/or its metabolites and evolution of the neutrophil count under treatment.
Methods

Population
Data were obtained from the ProGGRess (Pharmacokinetics of Ganciclovir and valGanciclovir triphosphate in Renal transplant patients) trial conducted in 22 adult renal transplant patients followed at the nephrology department of Limoges University Hospital, France. It was an ancillary study of the EPHEGREN study (no. 130-2013-30). All patients gave written informed consent. This trial complied with the Declaration of Helsinki amended in Tokyo and was reviewed and approved by the regional ethics committee of Limoges, France (no. 164-2015-01).
The patients received valganciclovir (Rovalcyte w , Roche, Switzerland) for prophylaxis of CMV infections. All patients were given valganciclovir at a dose of 450 mg once a day (19 patients) or 450 mg twice a day (3 patients) according to their creatinine clearance (as defined in the Summary of Product Characteristics), for 3 months (since transplantation). Exclusion criteria were prior valganciclovir treatment and granulocyte colony-stimulating factor intake. Demographic and clinical data for the 22 patients are summarized in Table 1 .
Blood sampling and drug analysis
All patients were sampled during the third month after transplantation. Samples were collected in EDTA tubes at pre-dose and 1, 2, 3 and 5 h after the valganciclovir morning dose. Cells and plasma were immediately isolated from whole blood using a classical Ficoll -dextran method. Cells were then counted and samples stored at 2208C. For each sample, ganciclovir in plasma was measured as well as ganciclovir, ganciclovir monophosphate and ganciclovir triphosphate in PBMCs. The concentrations were obtained using a validated LC-MS/MS method and intracellular form concentrations were normalized per million PBMCs as previously described. 8 Briefly, each intracellular form was isolated through a solidphase extraction Sep-Pak Accell Plus QMA cartridge (Waters Corporation, Milford, MA, USA) using a KCl gradient. The samples were then desalted and stored at 2208C until analysis. The LC-MS/MS method used a 4000 Qtrap w (Applied Biosystems, France) triple quadrupole linear ion-trap mass spectrometer.
PK modelling
All the PK profiles (plasma ganciclovir and intracellular ganciclovir, ganciclovir monophosphate and ganciclovir triphosphate) obtained from the 22 renal transplant patients were analysed using the non-parametric adaptive grid approach implemented in R software (PMetrics w version 1.3. 2 9 ). Several structural models were evaluated during the development process with and without absorption lag time. The analysis was based on a fourcompartment open model: absorption of valganciclovir was modelled as a first-order process and conversion into ganciclovir in the central compartment was assumed to be instantaneous (as previously described 10 ). As presented in Figure 1 , the model included a plasmatic compartment, an intracellular ganciclovir compartment and intracellular ganciclovir monophosphate and ganciclovir triphosphate compartments.
Screening and selection of covariates were performed as part of the population PK analysis, following a classical stepwise approach. The model was parameterized in terms of the absorption rate constant (K a ), renal clearance of the drug (CL), central volume of distribution of each compartment, K a and intercompartmental transfer rate constants (K n,n+1 ). The constant K 40 referred to the elimination of intracellular ganciclovir triphosphate (literally from compartment 4 to compartment 0). This elimination could be made both by integration into DNA (viral or cellular) or efflux of intracellular ganciclovir triphosphate from cells.
A linear error model was used to describe the analytical variability.
The performance of the model was assessed by studying its ability to estimate individual AUC values of each ganciclovir form. The mean bias between individual AUCs calculated using individual post hoc parameters and those obtained by the linear trapezoidal method was calculated.
Relationship between exposure to ganciclovir and evolution of the neutrophil count
The individual slope of the neutrophil count (from the beginning of treatment to the time of sampling, i.e. 3 months later) was used as the main criterion. A multiple linear regression analysis was performed to explore the influence of the following individual covariates on the individual slope: creatinine clearance; age; sex; valganciclovir dose; plasma ganciclovir AUC; AUCs of intracellular ganciclovir and its metabolites; C max and C trough ; CMV serology; and mycophenolate mofetil dose. Classically, a univariate analyse was first performed using a P value threshold of 0.1. In a second step, all significant covariates were included in an intermediate model. Finally, the final model was selected using a backward stepwise procedure based on the likelihood ratio test for the selection of the final model, using a P value threshold of 0.05.
Results
The observed concentration -time profiles of ganciclovir and its different metabolites in the 22 renal transplant patients are displayed in Figure 2 . The exposure indices are given in Table 2 . For each form, concentrations ,5 ng/mL (the limit of quantification of the analytical method) were considered as null and intracellular A model using 13 parameters plus a lag time to describe the absorption phase was necessary to determine the PK of plasma ganciclovir and intracellular ganciclovir, ganciclovir monophosphate and ganciclovir triphosphate. The PK parameters are given in Table 3 . Figure S1 (available as Supplementary data at JAC Online) illustrates the goodness of fit.
The relative bias between the reference (trapezoidal rule) and model estimated AUCs were 25.1% (minimum-maximum range:
234%-42%), 22.8% (226%-124%), 20.6% (260%-95%) and 29.6% (238%-74%) for plasma ganciclovir and intracellular ganciclovir, ganciclovir monophosphate and ganciclovir triphosphate, respectively.
The results of the multiple linear regression analysis investigating the relationships between individual covariates and evolution of the neutrophil count are given in Table 4 . The three exposure indices for intracellular ganciclovir triphosphate were significant in the univariate analysis. In the multivariate analysis, only the AUC 0 -5 of intracellular ganciclovir triphosphate was associated with the slope of the neutrophil count. The effect on the slope was b ¼ 20.0019+5×10 24 (P, 0.01) with a correlation r Spearman ¼ 20.64. This last result is illustrated in Figure 3 . As an example, this figure shows that the patient having the lowest
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AUC value (2.82 ng . h/mL/10 6 cells) had a gain of 10% in the neutrophil count, while the one having the highest AUC value (29.3 ng . h/mL/10 6 cells) had severe neutropenia (decrease of 87% in the neutrophil count).
Discussion
To our knowledge, we report the first study describing the PK of ganciclovir, including intracellular forms, in renal transplant patients given valganciclovir. To better explore the relationships between ganciclovir in plasma and its intracellular outcome, including the factors that may contribute to any interindividual variability, a population PK model was developed. Additionally, a significant relationship between intracellular ganciclovir triphosphate levels-i.e. the active intracellular form-and the decrease in the neutrophil count was reported.
In our population of 22 adult renal transplant patients, important interindividual variability in the exposure to valganciclovir was calculated. The observed T max was reached at 1.7+0.9 h with a concentration of 5900+3600 ng/mL for plasma ganciclovir and a mean trough concentration of 1000+1200 ng/mL. These values were consistent with those previously reported in similar populations 11, 12 or in a review article that reported a valganciclovir maximum plasma concentration of 3100+800 ng/mL after a dose of 450 mg and of 6600+1900 ng/mL after a dose of 900 mg with a T max of 3.0+1.0 h. 13 A non-parametric approach was chosen to describe the PK of both the plasmatic and intracellular forms of ganciclovir. Briefly, this approach does not make the assumption that PK parameters are normally distributed (or that any bimodal distribution could exist), but provides an estimate of the whole probability distribution of these PK parameters. It is recognized that this approach better describes the population PK parameters than parametric Results are given as mean+SD. Nineteen patients were given 450 mg and three were given 900 mg on the day of sampling. CL/F is the apparent clearance of ganciclovir; K n,n+1 is the rate constant from compartment n to compartment n +1 (1 refers to ganciclovir in plasma, 2 refers to intracellular ganciclovir, 3 refers to intracellular ganciclovir monophosphate and 4 refers to intracellular ganciclovir triphosphate); V1, V2, V3 and V4 are the apparent volumes of distribution for the four compartments.
Ganciclovir exposure effect in transplant patients 487 JAC methods when distributions are non-Gaussian and when the studied population is rather small (here N¼ 22 patients). 14 -16 If numerous studies explored ganciclovir concentrations in plasma, little is known about the intracellular outcome of ganciclovir. For intracellular ganciclovir triphosphate, we observed that T max was reached at 3 h with a concentration of 6 ng/mL and a mean trough concentration of 1.5 ng/mL per million PBMCs. However, a huge interindividual variability was observed.
Through multiple linear regression analysis, we found an association between the decrease in the neutrophil count during the first 3 months of treatment and intracellular ganciclovir triphosphate exposure. Precisely, the main exposure indices to intracellular ganciclovir triphosphate were significant in the univariate analysis (C trough , C max and AUC 0 -5 ) and, finally, the single significant covariate was AUC 0 -5 in the multivariate analysis. This was not the case for exposure to plasma ganciclovir, as previously reported. 7 Thirty years ago, Smee et al. 17 observed in vitro that intracellular ganciclovir triphosphate could persist in cells for 18 h after exposure to ganciclovir and that ganciclovir excretion from cells was very slow. These authors wrote that 'presumably, higher toxicity in these cell lines [HET and MET cell lines] may be correlated with higher levels of intracellular nucleoside triphosphate'. Moreover, in cells transfected with the viral thymidine kinase treated with ganciclovir, Halloran and Fenton 18 showed that the triphosphorylated form of ganciclovir is incorporated into the cellular DNA and arrests the cell cycle. Our result supports these hypotheses.
Therefore, the correlation between the AUC 0 -5 and neutrophil slope values is quite poor. For example, several patients have an AUC 0 -5 of 30 ng . h/mL/10 6 cells with a high variability in the slope of neutrophil count (decreasing from 0.02 to 0.1 G/L/day). It is likely that this biomarker is not the main one and other variables may play also a role in the decrease of the neutrophil count.
More precisely, the role of ganciclovir and intracellular ganciclovir triphosphate membrane transporters is probably important and is certainly involved in this variability among patients. Adachi et al. 19 reported that multidrug resistance protein 4 (MRP4) is involved in intracellular ganciclovir efflux. In a population of 206 renal transplant patients, we have identified an SNP known to decrease MRP4 activity 20 and that favours ganciclovir accumulation in neutrophils. 21 In that study, it was observed that the decrease in neutrophil count was more pronounced in patients carrying this SNP. Billat et al.
This study has some limitations. It is a monocentric study that included only 22 renal transplant patients. More patients would certainly be required to reach more meaningful conclusions concerning the correlation between AUC values and the slope of the neutrophil count. Additionally, while the neutrophil count was measured many times in each patient, exposure to ganciclovir was measured only during the third month after drug introduction and the valganciclovir dose, adapted according their creatinine clearance, may have changed during the treatment. This change was not reported and only the morning ganciclovir dose before the PK sampling was taken into account. A longitudinal follow-up with multiple measurements of ganciclovir exposure should be performed in further studies.
While valganciclovir is widely used as a CMV prophylactic or curative treatment, its haematological toxicity limits its efficacy. A classical therapeutic drug monitoring based on the measurement of plasma ganciclovir is probably unable to detect this toxicity. The results of the present study suggest that the measurement of intracellular ganciclovir triphosphate could better anticipate a decrease in the neutrophil count. The combination of this biomarker together with pharmacogenetic information about the transporters involved in the accumulation of ganciclovir in cells would probably be helpful.
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